CA2191773A1 - Stable gel formulation for topical treatment of skin conditions - Google Patents

Stable gel formulation for topical treatment of skin conditions

Info

Publication number
CA2191773A1
CA2191773A1 CA002191773A CA2191773A CA2191773A1 CA 2191773 A1 CA2191773 A1 CA 2191773A1 CA 002191773 A CA002191773 A CA 002191773A CA 2191773 A CA2191773 A CA 2191773A CA 2191773 A1 CA2191773 A1 CA 2191773A1
Authority
CA
Canada
Prior art keywords
gel formulation
stable gel
skin conditions
gel
topical treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002191773A
Other languages
French (fr)
Other versions
CA2191773C (en
Inventor
Prakash M. Charu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Prakash M. Charu
Allergan
Allergan, Inc.
Allergan Sales, Inc.
Allergan Sales, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prakash M. Charu, Allergan, Allergan, Inc., Allergan Sales, Inc., Allergan Sales, Llc filed Critical Prakash M. Charu
Publication of CA2191773A1 publication Critical patent/CA2191773A1/en
Application granted granted Critical
Publication of CA2191773C publication Critical patent/CA2191773C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Abstract

The present invention provides a stable gel formulation for topical treatment of skin conditions in humans. The stable gel formulation includes an active agent, having activity for treatment of acne and psoriasis, which is insoluble in water and a plurality of nonaqueous vehicles for both sotubilizing said active agent and forming a gel therewith enabling topical application of the gel to a skin condition.
The plurality of vehicles am each present in amounts, and in combination, m control release of the active agent from the gel to the skin condition.
CA002191773A 1994-06-07 1995-06-07 Stable gel formulation for topical treatment of skin conditions Expired - Lifetime CA2191773C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25509494A 1994-06-07 1994-06-07
US08/255,094 1994-06-07
PCT/US1995/007338 WO1995033489A1 (en) 1994-06-07 1995-06-07 Stable gel formulation for topical treatment of skin conditions

Publications (2)

Publication Number Publication Date
CA2191773A1 true CA2191773A1 (en) 1995-12-14
CA2191773C CA2191773C (en) 2004-08-10

Family

ID=22966815

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002191773A Expired - Lifetime CA2191773C (en) 1994-06-07 1995-06-07 Stable gel formulation for topical treatment of skin conditions

Country Status (13)

Country Link
US (2) US5914334A (en)
EP (2) EP1147778B1 (en)
AT (2) ATE336263T1 (en)
AU (1) AU693905B2 (en)
CA (1) CA2191773C (en)
DE (2) DE69526344T2 (en)
DK (1) DK1147778T3 (en)
ES (2) ES2173958T3 (en)
IL (3) IL114049A (en)
PT (1) PT1147778E (en)
TW (1) TW379143B (en)
WO (1) WO1995033489A1 (en)
ZA (1) ZA954599B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
IT1288708B1 (en) * 1996-10-17 1998-09-23 Achille Sandoli PHARMACEUTICAL COMPOSITION INCLUDING THOMETAMINE FOR THE TOPICAL TREATMENT OF ACNE VULGARIS.
EP0969847A1 (en) * 1997-02-20 2000-01-12 Allergan Sales, Inc. Tazarotene and corticosteroid treatment for psoriasis
DE69831336T2 (en) * 1997-06-11 2006-06-22 Allergan, Inc., Irvine TAZAROTES AND UVB PHOTOTHERAPY FOR THE TREATMENT OF PSORIASIS
JP2002512638A (en) * 1998-03-30 2002-04-23 ザ、プロクター、エンド、ギャンブル、カンパニー Skin care composition
US20020160995A1 (en) * 1998-08-03 2002-10-31 Easterling W. Jerry Medication and method for remediating existing scars through transdermal, topical delivery of calcium channel blockers
US20090098065A1 (en) * 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
MXPA02010542A (en) * 2000-04-26 2003-10-14 Watson Pharmaceuticals Inc Minimizing adverse experience associated with oxybutynin therapy.
US7029694B2 (en) 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
FR2830449B1 (en) * 2001-10-05 2004-04-23 Fabre Pierre Dermo Cosmetique USE OF TAZAROTENE FOR THE PREPARATION OF A NAIL VARNISH FOR THE TREATMENT AND / OR PREVENTION OF PSORIASIS AND A NAIL VARNISH CONTAINING IT
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
TR201815573T4 (en) * 2002-05-28 2018-11-21 Astrazeneca Ab Topically applicable pharmaceutical preparation.
US20040018220A1 (en) * 2002-07-26 2004-01-29 Chiou Consulting, Inc. Aqueous compositions for facial cosmetics
FR2848451B1 (en) * 2002-12-17 2007-01-12 Galderma Res & Dev PROCESS FOR THE CHEMICAL STABILIZATION OF A SOLUBILIZED RETINOID AND AQUEOUS COMPOSITION OBTAINED BY THE PROCESS COMPRISING AT LEAST ONE RETINOID IN SALIVED FORM
CA2510038A1 (en) * 2002-12-17 2004-07-01 Galderma Research & Development, S.N.C. Process for the chemical stabilization of a solubilized retinoid in a solvent using a base
DK1879595T3 (en) * 2005-05-10 2015-01-05 Dermipsor Ltd Preparations and Methods for the Treatment of Hyperproliferative Epidermal Diseases
AR054805A1 (en) * 2005-06-29 2007-07-18 Stiefel Laboratories TOPICAL COMPOSITIONS FOR SKIN TREATMENT
US20070060620A1 (en) * 2005-09-09 2007-03-15 John Sefton Use of RAR retinoid agonists to increase sperm count and sperm mobility in males
JP2009510087A (en) * 2005-09-30 2009-03-12 オーエムピー インコーポレーテッド Stable ascorbic acid composition
US20070269534A1 (en) * 2006-02-02 2007-11-22 Ramirez Jose E Methods of treating skin to enhance therapeutic treatment thereof
US20070178058A1 (en) * 2006-02-02 2007-08-02 Ramirez Jose E Methods of using stable ascorbic acid compositions
WO2007092312A2 (en) * 2006-02-03 2007-08-16 Stiefel Laboratories, Inc. Topical skin treating compositions
ES2560540T3 (en) 2006-03-31 2016-02-19 Stiefel Research Australia Pty Ltd Foamable suspension gel
MXPA06008988A (en) * 2006-08-08 2008-02-07 Fernando Ahumada Ayala Topical antiacne preparations containing retinoid (tazarotene or adapalene), antibiotic (clindamycin phosphate) and/or keratolytic (miscrosponged benzoyl peroxide).
US20080299182A1 (en) * 2007-03-01 2008-12-04 Shuyuan Zhang Methods and formulations for topical gene therapy
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
US20110117182A1 (en) * 2009-07-30 2011-05-19 Allergan, Inc. Combination of dapsone with other anti-acne agents
PL2544532T3 (en) 2010-03-12 2017-08-31 Monsanto Technology Llc Agrochemical gel compositions
CN103249402A (en) * 2010-10-08 2013-08-14 赫尔普百治疗有限公司 Novel composition
US10123987B2 (en) 2013-10-31 2018-11-13 Sun Pharmaceutical Industries Limited Topical pharmaceutical composition of acitretin
JP2022506944A (en) * 2018-11-08 2022-01-17 ヴァーソナ セラピューティクス，インコーポレーテッド Topical formulations of 5-α-reductase inhibitors and their use
US11311556B2 (en) 2020-05-13 2022-04-26 Varsona Therapeutics, Inc. Topical dutasteride emulsions for treating endocrine therapy-induced alopecia
KR20230039979A (en) * 2021-09-15 2023-03-22 서울대학교산학협력단 Gel composition for preventing or treating atopic dermatitis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3934028A (en) * 1974-04-22 1976-01-20 The Regents Of The University Of California Acne and psoriasis treatment with retinoic acid analogs
US4895727A (en) * 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
US4810804A (en) * 1987-03-26 1989-03-07 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a heterobicyclic group having retinoid-like activity
EP0481007B1 (en) * 1989-06-07 1997-01-22 BAZZANO, Gail S SLOW RELEASE VEHICLES FOR MINIMIZING SKIN IRRITANCY OF TOPICAL COMPOSITIONS containing retinoids
AU670777B2 (en) * 1992-04-16 1996-08-01 Ortho Pharmaceutical Corporation Aqueous gel vehicles for retinoids
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
DE69831336T2 (en) * 1997-06-11 2006-06-22 Allergan, Inc., Irvine TAZAROTES AND UVB PHOTOTHERAPY FOR THE TREATMENT OF PSORIASIS
US6017938A (en) * 1998-07-28 2000-01-25 Bershad; Susan Short contact treatment for acne
US6114348A (en) * 1999-03-10 2000-09-05 Weber; Paul J. Method of treating warts using tazarotene

Also Published As

Publication number Publication date
WO1995033489A1 (en) 1995-12-14
DE69535184T2 (en) 2007-08-23
US5914334A (en) 1999-06-22
AU2821895A (en) 1996-01-04
ZA954599B (en) 1996-01-26
ATE336263T1 (en) 2006-09-15
EP1147778B1 (en) 2006-08-16
CA2191773C (en) 2004-08-10
IL114049A0 (en) 1995-10-31
AU693905B2 (en) 1998-07-09
EP0764032B1 (en) 2002-04-10
PT1147778E (en) 2006-12-29
US6258830B1 (en) 2001-07-10
IL122358A (en) 2001-01-28
EP0764032A1 (en) 1997-03-26
ATE215836T1 (en) 2002-04-15
DE69526344T2 (en) 2002-11-07
TW379143B (en) 2000-01-11
DK1147778T3 (en) 2006-12-18
EP1147778A1 (en) 2001-10-24
DE69526344D1 (en) 2002-05-16
IL114049A (en) 2000-08-31
ES2269296T3 (en) 2007-04-01
IL122359A (en) 2001-08-26
DE69535184D1 (en) 2006-09-28
ES2173958T3 (en) 2002-11-01

Similar Documents

Publication Publication Date Title
CA2191773A1 (en) Stable gel formulation for topical treatment of skin conditions
WO1996012498A3 (en) Dermatological compositions containing benzoyl peroxide and a compound reducing skin irritation
CA2262870A1 (en) Liposome-based topical vitamin d formulation
CA2133086A1 (en) Skin care method and composition
WO2000027381A3 (en) Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions
CA2184433A1 (en) Retinoid Formulations in Porous Microspheres for Reduced Irritation and Enhanced Stability
CA2094084A1 (en) Aqueous gel vehicles for retinoids
MY135988A (en) Additive for improving the water resistance of cosmetic or dermatological formulations
CA2404810A1 (en) Topical composition having undifferentiated plant seed cells and method for using same
AU5789990A (en) Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
CA2244887A1 (en) Photoprotective compositions
CA2214884A1 (en) Poly(hydroxy acid)/polymer conjugates for skin applications
CA2165768A1 (en) Thermoplastic elastomeric copolymers and hair and skin care compositionscontaining the same
CA2159985A1 (en) Methods of Using Hesperetin for Sebum Control and Treatment of Acne
CA2291144A1 (en) Topical treatment of psoriasis using neutralizing antibodies to il-8
WO1997001343A3 (en) Utilization of sophorolipids as therapeutically active substances or cosmetic products, in particular for the treatment of the skin
CA2015838A1 (en) Method of topically treating acne vulgaris
CA2099188A1 (en) Use of a cosmetic composition
CA2190505A1 (en) Use of gel formulations as dressing agents
CA2140545A1 (en) Use of first runnings coconut fatty acid as insect-repellent
CA2207783A1 (en) Antiperspirant or deodorant composition comprising a moisturizing cream
CA2157836A1 (en) L-carnitine salt and cosmetic and pharmaceutical compositions containing same for treating dermatoses
ES2137125A1 (en) Use of the zinc salt of glycyrrhetic acid in preparations against acne, and the compositions which contain said salt.
EP0721775A3 (en) Combination of active agents efficcient against unhealthy skin, mild acne and grampositive bacteria
CA2322878A1 (en) Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20150608